Bausch + Lomb (BLCO) – Research Analysts’ Recent Ratings Updates

Bausch + Lomb (NYSE: BLCO) has recently received a number of price target changes and ratings updates:

• 11/2/2026 – Bausch + Lomb was downgraded by HC Wainwright from “buy” to “neutral”. They now have a $22.00 price target on the stock, up from $21.00.
• 10/31/2026 – Bausch + Lomb was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 10/30/2026 – Bausch + Lomb was upgraded by Zacks Research from “hold” to “strong-buy”.
• 10/29/2026 – Bausch + Lomb had its “hold” rating reaffirmed by Deutsche Bank. They now have a $20.00 price target on the stock.
• 10/29/2026 – Bausch + Lomb had its price target raised by Citigroup from $21.00 to $23.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Bausch + Lomb had its price target raised by JPMorgan Chase & Co. from $16.00 to $22.00. They now have a “neutral” rating on the stock.
• 10/29/2026 – Bausch + Lomb had its price target raised by Royal Bank Of Canada from $21.00 to $23.00. They now have an “outperform” rating on the stock.
• 10/29/2026 – Bausch + Lomb had its price target raised by Wells Fargo & Company from $18.00 to $19.00. They now have an “equal weight” rating on the stock.
• 10/7/2026 – Bausch + Lomb was upgraded by Barclays to “strong-buy”.
• 10/6/2026 – Bausch + Lomb is now covered by Barclays. They set an “overweight” rating and a $24.00 price target on the stock.
• 9/15/2026 – Bausch + Lomb had its “hold” rating reaffirmed by Needham & Company LLC.

Bausch + Lomb Stock Performance

Shares of BLCO stock opened at $21.14 on Friday. The company has a 50 day moving average price of $17.93 and a 200-day moving average price of $16.84. Bausch + Lomb Corporation has a 52 week low of $14.44 and a 52 week high of $21.40. The firm has a market capitalization of $7.57 billion, a PE ratio of -68.19, a P/E/G ratio of 0.56 and a beta of 0.52. The company has a quick ratio of 1.04, a current ratio of 1.56 and a debt-to-equity ratio of 0.78.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, October 28th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.13. Bausch + Lomb had a negative net margin of 2.05% and a positive return on equity of 5.01%. The company had revenue of $1.38 billion for the quarter, compared to the consensus estimate of $1.37 billion. During the same quarter in the prior year, the firm earned $0.18 earnings per share. The firm’s revenue for the quarter was up 7.3% compared to the same quarter last year. As a group, equities research analysts expect that Bausch + Lomb Corporation will post 0.94 earnings per share for the current year.

Insiders Place Their Bets

In other news, CAO Frederick Munsch sold 112,015 shares of the stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $20.48, for a total transaction of $2,294,067.20. Following the transaction, the chief accounting officer directly owned 45,831 shares of the company’s stock, valued at $938,618.88. This represents a 70.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.45% of the company’s stock.

Bausch + Lomb Corporation is an eye-health company that develops, manufactures and markets products for consumers, eye-care professionals and surgical teams. Its business spans vision care, pharmaceuticals and surgical devices. Its products include contact lenses and lens-care solutions, as well as eye-health medicines and nutritional supplements. The company also supplies equipment, technologies and related products used in eye surgery and other ophthalmic procedures. Founded in Rochester, New York, in 1853 by John Jacob Bausch and Henry Lomb, the company serves customers in more than 100 countries.